Loading
companiesCompany
Rigel Pharmaceuticals
Commercialises olutasidenib (Rezlidhia), an IDH1 inhibitor for relapsed AML, alongside fostamatinib.
Overview
Rigel Pharmaceuticals, based in South San Francisco and listed as RIGL, commercialises olutasidenib, sold as Rezlidhia, an IDH1 inhibitor for relapsed acute myeloid leukaemia, alongside fostamatinib. Olutasidenib was approved on 1 December 2022 for relapsed or refractory IDH1-mutated AML, and Rigel licensed it from Forma Therapeutics, later part of Novo Nordisk, in 2022. OnCo links it to acute myeloid leukaemia and to the olutasidenib drug record. Whether a second IDH1 inhibitor can take share from the first on durability or tolerability is the open question for a company that did not discover the drug it sells. Olutasidenib has its own page.
Headquarters
South San Francisco, CA, US
Scorecard
All companies#150of 1244 companies, score 39
- approved products +12
- targets +4
- modalities +2
- regions +5
- registry trials +16
2 approved, 0 in phase 3, 0 earlier, 2 targets, 64 registry studies. Formula on the scorecards page.
Type
Biotech · RIGL
Stage
Public
Website
ApprovedSmall-molecule IDH1 inhibitor
Olutasidenib · Rezlidhia
Olutasidenib is a second IDH1 inhibitor for relapsed AML, with a higher response rate in its pivotal cohort than ivosidenib had in its own.
EstablishedOral spleen tyrosine kinase (SYK) inhibitor
Fostamatinib · Tavalisse
Fostamatinib is a tablet that blocks the enzyme SYK so the spleen stops destroying antibody-coated platelets; it is approved for chronic immune thrombocytopenia and was first trialled as a lymphoma drug.
ApprovedSmall-molecule kinase inhibitor (RET)
Pralsetinib · Gavreto
Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.
Similar pages
- TechnologyIDH inhibitors
Shares Study of Olutasidenib and Temozolomide in HGG, Olutasidenib, Acute myeloid leukaemia.
- PathwayMutant IDH / 2-hydroxyglutarate
Shares Olutasidenib, Acute myeloid leukaemia.
- TermDifferentiation syndrome
Shares Olutasidenib, Acute myeloid leukaemia.
- BiomarkerIDH1 R132 mutation
Shares Olutasidenib, Acute myeloid leukaemia.
- CancerIDH1- and IDH2-mutated acute myeloid leukaemia
Shares Olutasidenib, Acute myeloid leukaemia.
cancers
fronts
drugs
EstablishedOral spleen tyrosine kinase (SYK) inhibitor
Fostamatinib · Tavalisse
ApprovedSmall-molecule IDH1 inhibitor
Olutasidenib · Rezlidhia
ApprovedSmall-molecule kinase inhibitor (RET)
Pralsetinib · Gavreto